Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-throughout sequencing of liver cancer cells treated Flavokawain C

ABSTRACT: The high-throughput sequencing technology was performed after the treatment of humanliverl cancer cells HUH-7 with Flavokawain C synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human liver cancer cells HUH-7 after the treatment of the active compound and to find an interesting target gene.

ORGANISM(S): Homo sapiens

PROVIDER: GSE242009 | GEO | 2023/11/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

High-throughout sequencing of colorectal cancer and non-small cell lung cancer cells treated actived compound YHM18

Project description:The high-throughput sequencing technology was performed after the treatment of human colorectal cancer cells HCT116 and non-small cell lung cancer cells A549 with the active compound YHM18 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human colorectal cancer cells HCT116 and non-small cell lung cancer cells A549 after the treatment of the active compound and to find an interesting target gene, GTSE1.

2024-11-11 | GSE241518 | GEO

High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

Project description:The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 with the active compound D16 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 after the treatment of the active compound Changes to explore the effect of active compounds on the proliferation and motility of triple breast breast cancer cells and to find an interesting target gene, CKAP2.

2021-08-17 | GSE182063 | GEO

High-throughout sequencing of triple negative breast cancer cells treated with Lespedeza bicolor root

Project description:The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 and BT549 with Lespedeza bicolor root extracted by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 and BT549 after the treatment of Lespedeza bicolor root changes, and to find an interesting target gene.

2024-03-27 | GSE262226 | GEO

High-throughput sequencing of OS cells treated with activated compound B5.

Project description:The high-throughput sequencing technology was performed after the treatment of human osteosarcoma cells U2OS and MG63 with the active compound B5 designed and synthesized by ourselves, to explore the expression of genes related to cell adhesion, migration and invasion of human osteosarcoma cells U2OS and MG63 after the treatment of the active compound Changes to explore the effect of active compounds on the motility of osteosarcoma cells.

2020-08-25 | GSE156729 | GEO

High-throughout sequencing of ovarian cancer cells treated with TMPyP4 and H2O2

Project description:The high-throughput sequencing technology was performed after the treatment of human ovarian cancer cells A2780 with TMPyP4 and H2O2 purchased from Sigma-Aldrich, to explore the expression of genes related to cell proliferation, DNA damage and ROS levels of ovarian cancer cells A2780 after the treatment of TMPyP4 and H2O2, and to find an interesting target pathway,HIF-1 signaling pathway.

2024-03-25 | GSE262015 | GEO

Reactivation of mutant p53 by SLMP53-2: a promising therapeutic option against hepatocellular carcinoma

Project description:In order to pursue the search for new reactivators of mutant p53, a small library of molecules was synthesized starting from a previously established lead (SLMP53-1). The molecules were tested in various cell-based assays and one, herein referred to as SLMP53-2, displayed a marked reduction of the IC50 values in NCI-H1299 cells expressing the p53 mutants (mutp53) R175H, Y220C, G245S, R248Q, R273C, and R273H. The activity of SLMP53-2 was then investigated using cancer cells lines expressing endogenous mutant p53 and focusing on hepatocellular carcinoma HuH-7 and breast ductal carcinoma HCC1419 cells endogenously expressing mutp53-Y220C. In HuH-7 cells, SLMP53-2 displayed a concentration-dependent growth inhibitory effect on colony formation, restored wt-like p53 protein conformation and transcriptional activity and displayed in vivo antitumour activity in a xenograft mouse model, with no apparent toxicity for normal tissues. To investigate more deeply the impact of SLMP53-2 treatments on gene expression in HuH-7 cells we performed microarray-based analysis using two different concentrations of the compound, corresponding to 2x and 3x IC50. We also employed the MDM2 inhibitor Nutlin alone or in combination with 2x IC50 SLMP53-2.

2020-04-13 | GSE124021 | GEO

Huh-7 Over-expression FNDC4 LC-MS

Project description:To clarify the molecular mechanism by which FNDC4 promotes HCC invasion, mass spectrometry (MS) analysis was performed on the lysates of Huh-7-overexpressing FNDC4 and normal Huh-7 cells.

2022-02-17 | PXD025623 | Pride

Effects of PPARgamma-inactive Delta-2-TGZ on breast cancer cells MCF-7

Project description:TGZ is an agonist of the nuclear receptor PPARgamma. This synthetic compound displays anticancer effects on breast cancer cells but some of them are PPARgamma independent. Delta-2-TGZ (delta-2-troglotazone) is a PPARgamma inactive TGZ derivative possessing a double bond adjoining the thiazolidinedione ring. This compound still displays anticancer efefcts. It is an interesting tool to study the PPARgamma-independent mechanisms. We used microarrays to examine the global programme of gene expression in response to Delta-2-TGZ treatment in MCF7 cell line.

2017-07-07 | GSE99941 | GEO

High-throughout sequencing of RAW264.7 cells treated with LPS and Harmine

Project description:After stimulation of RAW264.7 cells with LPS and Harmine, high-throughput sequencing technology was used to explore the changes in the inflammation level of RAW cells and the enrichment of signaling pathways after LPS and Harmine treatment, and to find an interesting target pathway.

2024-05-20 | GSE267507 | GEO

JQ1 promotes invasion in a BET protein independent manner in prostate cancer

Project description:Recent findings have shown that inhibitors targeting BET (bromodomain and extraterminal domain) proteins, such as the small molecule JQ1, are potent growth inhibitors of many cancers and hold promise for cancer therapy. However, some reports also have revealed that JQ1 can activate additional oncogenic pathways and may affect EMT (epithelial mesenchymal transition). Therefore, it is important to address the potential unexpected effect of JQ1 treatment, such as cell invasion and metastasis. Here, we showed that in prostate cancer, JQ1 inhibited cancer cell growth but promoted invasion and metastasis in a BET protein independent manner. Multiple invasion pathways including EMT, BMP (bone morphogenetic protein) signaling, chemokine signaling and focal adhesion pathway were activated by JQ1 to promote invasion. Notably, JQ1 induced upregulation of invasion genes through inhibition of FOXA1, an invasion suppressor in prostate cancer. JQ1 directly interacted with FOXA1, inactivated FOXA1 binding to its interacting repressors, TLE3, HDAC7 and NFIC, thus blocking FOXA1 repressive function and activating the invasion genes. Our finding indicates that JQ1 has an unexpected effect of promoting invasion in prostate cancer. Thus, the ill effect of JQ1 or its derived therapeutic agents could not be ignored during cancer treatment, especially in FOXA1 related cancers.

2022-10-01 | GSE139230 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data